CeQur acquires license for an insulin delivery device

CeQur plans to launch Calibra’s insulin delivery device under a new name in mid-2019, following transfer of manufacturing equipment. “CeQur is dedicated to simplifying insulin dosing for people with diabetes, so that they can live healthier, more satisfying lives,” said Robert Farra, chief executive officer of CeQur. “Clinical studies and real-world experience have shown that wearable, on-demand insulin delivery provides an ideal solution to the pervasive challenge of mealtime insulin delivery. The Calibra device is a perfect complement to PAQ, our basal and bolus insulin-infusion device. Both wearable devices provide simple, discreet, three-day insulin delivery without the barriers and discomfort created by injections.”

CeQur is incorporated in Switzerland. Presently, the CFO Douglas Gunthardt leads the finance operations from here. In 2015, the company caused a stir with its $100 million Series C financing round.

Apart from the acquired device CeQur is developing PAQ, a wearable insulin delivery device that delivers up to 3 days of continuous pre-set basal insulin plus on- demand mealtime bolus in 2 unit increments. The premarket submission to the FDA for PAQ is on schedule for the fourth quarter of this year.

PAQ and the Calibra device provide two different and distinct options for patients and healthcare providers to more tightly manage blood glucose control. Patients who prefer to maintain their established basal insulin routine – especially those who are altering their daily basal dose frequently – will likely use the bolus-only device (the Calibra device). Those who prefer to eliminate all injections for three days – both basal and bolus - will likely choose the PAQ.

(Press release / SK)